

Robert C Read

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4453407/publications.pdf>

Version: 2024-02-01

49
papers

3,658
citations

257450

24
h-index

189892

50
g-index

53
all docs

53
docs citations

53
times ranked

4766
citing authors

#	ARTICLE	IF	CITATIONS
1	Neisseria lactamica Controlled Human Infection Model. <i>Methods in Molecular Biology</i> , 2022, 2414, 387-404.	0.9	3
2	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. <i>Lancet, The</i> , 2022, 399, 36-49.	13.7	161
3	Public attitudes to a human challenge study with SARS-CoV-2: a mixed-methods study. <i>Wellcome Open Research</i> , 2022, 7, 49.	1.8	3
4	Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. <i>Nature Medicine</i> , 2022, 28, 1031-1041.	30.7	281
5	Antibiotics for lower respiratory tract infection in children presenting in primary care (ARTIC-PC): the predictive value of molecular testing. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1238-1244.	6.0	3
6	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.. <i>Journal of Infection</i> , 2022, 84, 795-813.	3.3	43
7	Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. <i>Lancet Infectious Diseases, The</i> , 2022, 22, 1131-1141.	9.1	99
8	Controlled human infection with <i>Neisseria lactamica</i> in late pregnancy to measure horizontal transmission and microbiome changes in mother-neonate pairs: a single-arm interventional pilot study protocol. <i>BMJ Open</i> , 2022, 12, e056081.	1.9	3
9	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. <i>Lancet Respiratory Medicine, the</i> , 2022, 10, 1049-1060.	10.7	24
10	Manipulating the infant respiratory microbiomes to improve clinical outcomes: A review of the literature. <i>Journal of Infection</i> , 2021, 82, 247-252.	3.3	4
11	A recombinant commensal bacteria elicits heterologous antigen-specific immune responses during pharyngeal carriage. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	7
12	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. <i>Lancet, The</i> , 2021, 398, 856-869.	13.7	430
13	Antibiotics for lower respiratory tract infection in children presenting in primary care in England (ARTIC PC): a double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2021, 398, 1417-1426.	13.7	32
14	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. <i>Lancet, The</i> , 2021, 398, 2258-2276.	13.7	519
15	Controlled Human Infection With <i>Bordetella pertussis</i> Induces Asymptomatic, Immunizing Colonization. <i>Clinical Infectious Diseases</i> , 2020, 71, 403-411.	5.8	40
16	Overcoming Waning Immunity in Pertussis Vaccines: Workshop of the National Institute of Allergy and Infectious Diseases. <i>Journal of Immunology</i> , 2020, 205, 877-882.	0.8	17
17	Reducing risks from coronavirus transmission in the home—the role of viral load. <i>BMJ, The</i> , 2020, 369, m1728.	6.0	48
18	Exploring the acceptability of controlled human infection with SARS-CoV-2—a public consultation. <i>BMC Medicine</i> , 2020, 18, 209.	5.5	18

#	ARTICLE	IF	CITATIONS
19	A qPCR assay for <i>Bordetella pertussis</i> cells that enumerates both live and dead bacteria. PLoS ONE, 2020, 15, e0232334.	2.5	3
20	The infant pharyngeal microbiomes: origin, impact and manipulation. Current Opinion in Infectious Diseases, 2020, 33, 548-555.	3.1	6
21	Protocol for a controlled human infection with genetically modified <i>Neisseria lactamica</i> expressing the meningococcal vaccine antigen NadA: a potent new technique for experimental medicine. BMJ Open, 2019, 9, e026544.	1.9	6
22	<i>Neisseria meningitidis</i> and meningococcal disease: recent discoveries and innovations. Current Opinion in Infectious Diseases, 2019, 32, 601-608.	3.1	13
23	The nonpathogenic commensal <i>Neisseria</i> : friends and foes in infectious disease. Current Opinion in Infectious Diseases, 2019, 32, 490-496.	3.1	21
24	PERISCOPE: road towards effective control of pertussis. Lancet Infectious Diseases, The, 2019, 19, e179-e186.	9.1	67
25	Genomes of <i>Escherichia coli</i> bacteraemia isolates originating from urinary tract foci contain more virulence-associated genes than those from non-urinary foci and neutropaenic hosts. Journal of Infection, 2018, 77, 534-543.	3.3	9
26	Microevolution of <i>Neisseria lactamica</i> during nasopharyngeal colonisation induced by controlled human infection. Nature Communications, 2018, 9, 4753.	12.8	24
27	Malaria systems immunology: <i>Plasmodium vivax</i> induces tolerance during primary infection through dysregulation of neutrophils and dendritic cells. Journal of Infection, 2018, 77, 440-447.	3.3	29
28	Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia. ERJ Open Research, 2018, 4, 00028-2018.	2.6	41
29	A role for the tetraspanin proteins in <i>Salmonella</i> infection of human macrophages. Journal of Infection, 2017, 75, 115-124.	3.3	9
30	A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine. Vaccine, 2017, 35, 427-434.	3.8	34
31	Investigating <i>Bordetella pertussis</i> colonisation and immunity: protocol for an inpatient controlled human infection model. BMJ Open, 2017, 7, e018594.	1.9	26
32	International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. European Respiratory Journal, 2017, 50, 1700582.	6.7	792
33	<i>Neisseria lactamica</i> Y92a1009 complete genome sequence. Standards in Genomic Sciences, 2017, 12, 41.	1.5	6
34	Modulation of Human Airway Barrier Functions during <i>Burkholderia thailandensis</i> and <i>Francisella tularensis</i> Infection. Pathogens, 2016, 5, 53.	2.8	5
35	Analysis of histone post translational modifications in primary monocyte derived macrophages using reverse phase—reverse phase chromatography in conjunction with porous graphitic carbon stationary phase. Journal of Chromatography A, 2016, 1453, 43-53.	3.7	6
36	The environmental deposition of influenza virus from patients infected with influenza A(H1N1)pdm09: Implications for infection prevention and control. Journal of Infection and Public Health, 2016, 9, 278-288.	4.1	32

#	ARTICLE	IF	CITATIONS
37	Peptides from Tetraspanin CD9 Are Potent Inhibitors of Staphylococcus Aureus Adherence to Keratinocytes. PLoS ONE, 2016, 11, e0160387.	2.5	26
38	<i>Neisseria meningitidis</i> serogroup B bivalent factor H binding protein vaccine. Expert Review of Vaccines, 2015, 14, 493-503.	4.4	18
39	Neisserial Molecular Adaptations to the Nasopharyngeal Niche. Advances in Microbial Physiology, 2015, 66, 323-355.	2.4	24
40	Nasal Inoculation of the Commensal <i>Neisseria lactamica</i> Inhibits Carriage of <i>Neisseria meningitidis</i> by Young Adults: A Controlled Human Infection Study. Clinical Infectious Diseases, 2015, 60, 1512-1520.	5.8	95
41	Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial "in hibernation"™, ready for rapid activation. Health Technology Assessment, 2015, 19, 1-78.	2.8	15
42	Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet, The, 2014, 384, 2123-2131.	13.7	247
43	Anti-adhesion methods as novel therapeutics for bacterial infections. Expert Review of Anti-Infective Therapy, 2012, 10, 1457-1468.	4.4	77
44	Professional challenges and opportunities in clinical microbiology and infectious diseases in Europe. Lancet Infectious Diseases, The, 2011, 11, 408-415.	9.1	38
45	Cooperative Role for Tetraspanins in Adhesin-Mediated Attachment of Bacterial Species to Human Epithelial Cells. Infection and Immunity, 2011, 79, 2241-2249.	2.2	38
46	Nasopharyngeal Colonization by <i>Neisseria lactamica</i> and Induction of Protective Immunity against <i>Neisseria meningitidis</i> . Clinical Infectious Diseases, 2011, 52, 70-77.	5.8	70
47	Kinetics of Immune Responses to Nasal Challenge With Meningococcal Polysaccharide One Year After Serogroup-C Glycoconjugate Vaccination. Clinical Infectious Diseases, 2011, 52, 1317-1323.	5.8	14
48	Phase I Safety and Immunogenicity Study of a Candidate Meningococcal Disease Vaccine Based on <i>Neisseria lactamica</i> Outer Membrane Vesicles. Vaccine Journal, 2009, 16, 1113-1120.	3.1	55
49	<i>Haemophilus influenzae</i> Infection of Human Respiratory Mucosa in Low Concentrations of Antibiotics. The American Review of Respiratory Disease, 1993, 148, 201-207.	2.9	32